Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1976 1
1979 1
1980 1
1983 1
1985 4
1986 1
1988 1
1991 1
1993 2
1995 1
1996 1
1998 2
1999 1
2000 3
2001 1
2002 1
2003 1
2004 1
2005 4
2006 3
2007 1
2008 2
2009 4
2010 2
2011 2
2012 5
2013 4
2014 5
2015 1
2016 5
2017 8
2018 6
2019 6
2020 7
2021 19
2022 28
2023 21
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

145 results

Results by year

Filters applied: . Clear all
Page 1
Alopecia areata: a review on diagnosis, immunological etiopathogenesis and treatment options.
Sterkens A, Lambert J, Bervoets A. Sterkens A, et al. Clin Exp Med. 2021 May;21(2):215-230. doi: 10.1007/s10238-020-00673-w. Epub 2021 Jan 1. Clin Exp Med. 2021. PMID: 33386567 Review.
The prognosis is uncertain and is negatively influenced by the subtypes alopecia totalis and alopecia universalis and characteristics such as associated nail lesions, hair loss for more than 10 years and a positive familial history. The unpredictable course of the disease …
The prognosis is uncertain and is negatively influenced by the subtypes alopecia totalis and alopecia universalis and characteristics such a …
Platelet-Rich Plasma as a Treatment for Androgenetic Alopecia.
Gupta AK, Cole J, Deutsch DP, Everts PA, Niedbalski RP, Panchaprateep R, Rinaldi F, Rose PT, Sinclair R, Vogel JE, Welter RJ, Zufelt MD, Puig CJ. Gupta AK, et al. Dermatol Surg. 2019 Oct;45(10):1262-1273. doi: 10.1097/DSS.0000000000001894. Dermatol Surg. 2019. PMID: 30882509 Review.
Therapeutic management in paediatric alopecia areata: A systematic review.
Waśkiel-Burnat A, Kołodziejak M, Sikora M, Stochmal A, Rakowska A, Olszewska M, Rudnicka L. Waśkiel-Burnat A, et al. J Eur Acad Dermatol Venereol. 2021 Jun;35(6):1299-1308. doi: 10.1111/jdv.17187. J Eur Acad Dermatol Venereol. 2021. PMID: 33630354 Review.
Topical glucocorticosteroids (81%; 35/43), systemic Janus kinase (JAK) inhibitors (90%; 27/30), topical calcineurin inhibitors (42%; 8/19), topical JAK inhibitors (65%; 11/17), PUVA therapy (56%; 9/16) and 308-nm excimer laser (77%; 10/13) were also evaluated. Addit …
Topical glucocorticosteroids (81%; 35/43), systemic Janus kinase (JAK) inhibitors (90%; 27/30), topical calcineurin inhibitors (42%; 8/19), …
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--PART 1.
Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E; American Association of Clinical Endocrinologists (AACE); American College of Endocrinology (ACE); Androgen Excess and PCOS Society (AES). Goodman NF, et al. Endocr Pract. 2015 Nov;21(11):1291-300. doi: 10.4158/EP15748.DSC. Endocr Pract. 2015. PMID: 26509855
New ultrasound machines allow diagnosis of PCOM in patients having at least 25 small follicles (2 to 9 mm) in the whole ovary. Ovarian size at 10 mL remains the threshold between normal and increased ovary size. ...The choice of antiandrogen therapy is guided by sym …
New ultrasound machines allow diagnosis of PCOM in patients having at least 25 small follicles (2 to 9 mm) in the whole ovary. Ovarian size …
Relative Efficacy of Minoxidil and the 5-alpha Reductase Inhibitors in Androgenetic Alopecia Treatment of Male Patients: A Network Meta-analysis.
Gupta AK, Venkataraman M, Talukder M, Bamimore MA. Gupta AK, et al. JAMA Dermatol. 2022 Mar 1;158(3):266-274. doi: 10.1001/jamadermatol.2021.5743. JAMA Dermatol. 2022. PMID: 35107565 Free PMC article.
MAIN OUTCOMES AND MEASURES: Study end points were change in total and terminal hair count after 24 and 48 weeks of therapy. The 4 end points were quantified in hairs per square centimeters. ...The findings of this meta-analysis contribute to the comparative effectiveness l …
MAIN OUTCOMES AND MEASURES: Study end points were change in total and terminal hair count after 24 and 48 weeks of therapy. The 4 end …
Bicalutamide and the new perspectives for female pattern hair loss treatment: What dermatologists should know.
Carvalho RM, Santos LDN, Ramos PM, Machado CJ, Acioly P, Frattini SC, Barcaui CB, Donda ALV, Melo DF. Carvalho RM, et al. J Cosmet Dermatol. 2022 Oct;21(10):4171-4175. doi: 10.1111/jocd.14773. Epub 2022 Feb 10. J Cosmet Dermatol. 2022. PMID: 35032336 Review.
This review aimed to summarize and discuss the key information on this new therapy for FPHL. Bicalutamide has no diuretic effect. It does not cross the blood-brain barrier, and it has little effect on serum luteinizing hormone. ...
This review aimed to summarize and discuss the key information on this new therapy for FPHL. Bicalutamide has no diuretic effect. It …
Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis.
Wei D, Chen Y, Shen Y, Xie B, Song X. Wei D, et al. Front Immunol. 2023 Apr 17;14:1152513. doi: 10.3389/fimmu.2023.1152513. eCollection 2023. Front Immunol. 2023. PMID: 37138884 Free PMC article.
Oral baricitinib, tofacitinib, and ruxolitinib treatments significantly improved the complete response rate compared to placebo [MD = 12.21, 95% CI (3.41, 43.79)], [MD = 10.16, 95% CI (1.02, 101.54)], and [MD = 9.79, 95% CI, (1.29, 74.27)], respectively. ...However, furthe …
Oral baricitinib, tofacitinib, and ruxolitinib treatments significantly improved the complete response rate compared to placebo [MD = 12.21, …
Diagnosis of hyperandrogenism: clinical criteria.
Yildiz BO. Yildiz BO. Best Pract Res Clin Endocrinol Metab. 2006 Jun;20(2):167-76. doi: 10.1016/j.beem.2006.02.004. Best Pract Res Clin Endocrinol Metab. 2006. PMID: 16772149 Review.
Hyperandrogenism or androgen excess is a common endocrine disorder of women of reproductive-age, with a prevalence of 5-10%. The majority of patients with hyperandrogenism will have polycystic ovary syndrome. ...
Hyperandrogenism or androgen excess is a common endocrine disorder of women of reproductive-age, with a prevalence of 5-10%. The majo …
Treatment Patterns and Treatment Satisfaction Among Adults with Alopecia Areata in the United States.
Fridman M, Ray M, Gandhi K, Shy ME, Mostaghimi A. Fridman M, et al. Adv Ther. 2022 Dec;39(12):5504-5513. doi: 10.1007/s12325-022-02338-4. Epub 2022 Oct 12. Adv Ther. 2022. PMID: 36223027 Free PMC article.
At the time of survey, 45% of patients were being prescribed a combination of corticosteroids, 21% injectable corticosteroids, 11% topical corticosteroids/topical calcineurin inhibitor, and 10% immunomodulator as monotherapy or in combination. The majority (65%) of patient …
At the time of survey, 45% of patients were being prescribed a combination of corticosteroids, 21% injectable corticosteroids, 11% topical c …
Review of Superficial Cryotherapy for the Treatment of Alopecia Areata.
Kaiser M, Issa N, Yaghi M, Jimenez JJ, Issa NT. Kaiser M, et al. J Drugs Dermatol. 2023 Aug 1;22(8):802-809. doi: 10.36849/jdd.7431. J Drugs Dermatol. 2023. PMID: 37556514 Review.
Three studies compared cryotherapy with intralesional corticosteroid injection, and 2 studies compared cryotherapy with topical corticosteroid therapy. There was no statistically significant difference in efficacy, but there is some evidence to suggest that relapse rates w …
Three studies compared cryotherapy with intralesional corticosteroid injection, and 2 studies compared cryotherapy with topical corticostero …
145 results